Single- center experience with both Axicabtagene-ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL): Number of prior therapy lines is not associated with progression-free survival-论文-万方医学网

Single- center experience with both Axicabtagene-ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL): Number of prior therapy lines is not associated with progression-free survival

导出原文传递

翻译打印收藏纠错

作者： Buecklein, V ^[1] ; Blumenberg, V ^[2] ; Ackermann, J. ^[3] ; Schmidt, C. ^[4] ; Rejeski, K. ; Ruzicka, M. ; Mueller, N. ; Reischer, A. ; Busch, G. ; von Baumgarten, L. ; Humpe, A. ; von Bergwelt, M. ; Subklewe, M.

作者单位： Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, Munich, Germany ^[1] Ludwig Maximilians Univ Munchen, Gene Ctr, Translat Canc Immunol, Munich, Germany ^[2] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Neurol, Munich, Germany ^[3] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Transfus Med, Munich, Germany ^[4]

发布时间 2022-09-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除